Arialys Therapeutics

News

April 22, 2026

Arialys Presents Phase 1 ART5803 Data at AAN 2026

Arialys Therapeutics presented first-in-human Phase 1 safety and pharmacokinetic data for ART5803 at the American Academy of Neurology (AAN) Annual Meeting, held April 18–22, 2026, in Chicago.

The poster described safety, tolerability, and pharmacokinetic findings from two studies in healthy volunteers, including ART5803 concentrations in serum and cerebrospinal fluid and its pharmacokinetic profile following IVIG administration.

View the poster: ART5803 Phase 1 Clinical Safety and Pharmacokinetic Profile

Sign up for news updates

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News

Sign up for news updates

Follow us